Last reviewed · How we verify
Topical Antibiotic Product
At a glance
| Generic name | Topical Antibiotic Product |
|---|---|
| Also known as | Erythromycin, Bacitracin, Polysporin-Bacitracin |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (PHASE3)
- Topical Vancomycin for Neurosurgery Wound Prophylaxis (PHASE3)
- Efficacy of Hydrocolloid Dressing vs. Topical Antibiotic on Wound Healing of Post-Punch Biopsy Wounds (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Antibiotic Product CI brief — competitive landscape report
- Topical Antibiotic Product updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI